ARTICLE | Company News
Atrix submits Leuprogel NDA
March 27, 2001 8:00 AM UTC
ATRX submitted an NDA for its one month Leuprogel 7.5 mg leuprolide product to treat advanced prostate cancer. Leuprogel is injected subcutaneously, where it releases leuprolide, a luteinizing hormone...